Taro Pharmaceuticals just announced that they have partnered with BioPlus as the exclusive dispenser of the new specialty generic medication deferiprone.
Deferiprone (the generic form of Ferriprox®) treats transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate. Thalassemia is a genetic-based group of blood disorders that can cause anemia due to changes in hemoglobin.
Although thalassemia syndromes are considered rare in the United States, they are still the most common autosomal recessive disorders. These syndromes affect an estimated 1 in 100,000 people. Even with treatment, these syndromes can be associated with the complication of iron overload, due to frequent blood transfusions.
If you’re looking for a generic iron chelator option for your patients with thalassemia syndromes, know that deferiprone is now here and available from BioPlus. Thank you, Taro Pharmaceuticals for choosing BioPlus as the exclusive distributor of this medication. And, as always, you can count on BioPlus for the specialty pharmacy medications your patients need.
Related Posts
Psoriasis: Can Sleep Troubles be a Red Flag?
The calling card of psoriasis is uncomfortable skin symptoms, such as red patches of dry, cracked...
World Psoriasis Day
This week it’s all about bringing attention to psoriasis and psoriatic arthritis as we close in on...
Relief for Post-Shingles Pain
The painful rash and blistering scabs of shingles cause a huge amount of discomfort in the United...
Beyond Skin: Psoriasis and Health Risks
More than 7 million Americans experience psoriasis, the skin condition that creates dry, scaly,...